Gadi Lalazar1, Tomer Adar, Yaron Ilan. 1. Gastroenterology and Liver Units, Department of Medicine, Hadassah-Hebrew University Medical Center, Ein-Kerem, Jerusalem, Israel.
Abstract
AIM: To assess the role of the (13)C-methacetin breath test (MBT) in patients with acute liver disease. METHODS: Fifteen patients with severe acute liver disease from diverse etiologies were followed-up with (13)C-MBT during the acute phase of their illnesses (range 3-116 d after treatment). Patients fasted for 8 h and ingested 75 mg of methacetin prior to the MBT. We compared results from standard clinical assessment, serum liver enzymes, synthetic function, and breath test scores. RESULTS: Thirteen patients recovered and two patients died. In patients that recovered, MBT parameters improved in parallel with improvements in lab results. Evidence of consistent improvement began on day 3 for MBT parameters and between days 7 and 9 for blood tests. Later convergence to normality occurred at an average of 9 d for MBT parameters and from 13 to 28 d for blood tests. In both patients that died, MBT parameters remained low despite fluctuating laboratory values. CONCLUSION: The (13)C-MBT provides a rapid, non-invasive assessment of liver function in acute severe liver disease of diverse etiologies. The results of this pilot clinical trial suggest that the MBT may offer greater sensitivity than standard clinical tests for managing patients with severe acute liver disease.
AIM: To assess the role of the (13)C-methacetin breath test (MBT) in patients with acute liver disease. METHODS: Fifteen patients with severe acute liver disease from diverse etiologies were followed-up with (13)C-MBT during the acute phase of their illnesses (range 3-116 d after treatment). Patients fasted for 8 h and ingested 75 mg of methacetin prior to the MBT. We compared results from standard clinical assessment, serum liver enzymes, synthetic function, and breath test scores. RESULTS: Thirteen patients recovered and two patientsdied. In patients that recovered, MBT parameters improved in parallel with improvements in lab results. Evidence of consistent improvement began on day 3 for MBT parameters and between days 7 and 9 for blood tests. Later convergence to normality occurred at an average of 9 d for MBT parameters and from 13 to 28 d for blood tests. In both patients that died, MBT parameters remained low despite fluctuating laboratory values. CONCLUSION: The (13)C-MBT provides a rapid, non-invasive assessment of liver function in acute severe liver disease of diverse etiologies. The results of this pilot clinical trial suggest that the MBT may offer greater sensitivity than standard clinical tests for managing patients with severe acute liver disease.
Authors: E C Nista; L Fini; A Armuzzi; M Candelli; M A Zocco; I A Cazzato; G Merra; R Finizio; L Miele; A Grieco; G Gasbarrini; A Gasbarrini Journal: Eur Rev Med Pharmacol Sci Date: 2004 Jan-Feb Impact factor: 3.507
Authors: Paul J Gow; Stephen Warrilow; Steve Lontos; John Lubel; Sarah Wongseelashote; Gerry C MacQuillan; Robert M Jones; Rinaldo Bellomo; Peter W Angus Journal: Liver Transpl Date: 2007-12 Impact factor: 5.799
Authors: M L Shiffman; V A Luketic; A J Sanyal; P F Duckworth; P P Purdum; M J Contos; A S Mills; L E Edinboro; A Poklis Journal: Hepatology Date: 1994-04 Impact factor: 17.425
Authors: Kevin C Cossel; Eleanor M Waxman; Ian A Finneran; Geoffrey A Blake; Jun Ye; Nathan R Newbury Journal: J Opt Soc Am B Date: 2016-12-14 Impact factor: 2.106
Authors: Anna Kasicka-Jonderko; Anna Nita; Krzysztof Jonderko; Magdalena Kamińska; Barbara Błońska-Fajfrowska Journal: World J Gastroenterol Date: 2011-12-07 Impact factor: 5.742